MR
Martin P Rosendale
Chief Executive OfficerDirector

Martin P Rosendale insider trades: Cytomedix (CMXI) stock purchases

Chief Executive Officer, Cytomedix Last trade Aug 20, 2014 26 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2008
3
Companies
last trade 2014

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Martin reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 20, 2014CMXI↑ Buy$10K
Apr 4, 2013CMXI↑ Buy$9K
Feb 22, 2013CMXI↑ Buy$11K
Jul 3, 2012CMXI↑ Buy$9K
Mar 31, 2011CMXI↑ Buy$7K
Aug 14, 2009GTF↑ Buy$10K
May 22, 2009GTF↑ Buy$2K
Jan 7, 2009GTF↑ Buy$2K
Sep 5, 2008GTF↑ Buy$25K
Apr 3, 2008GTF↑ Buy$9K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Martin P Rosendale's insider trades

Martin P Rosendale is Chief Executive Officer at Cytomedix (CMXI). Since Apr 3, 2008, Martin has reported 10 open-market purchases worth $93K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include other transactions (12 filings), grants and awards (5 filings), option exercises (2 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CMXI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.